Aura Biosciences Inc Cash Flow Conversion Efficiency
Aura Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Aura Biosciences Inc (AURA) has a cash flow conversion efficiency ratio of -0.279x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.89 Million) by net assets ($107.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aura Biosciences Inc (2019–2025)
Cash flow conversion efficiency of Aura Biosciences Inc from 2019 to 2025. This chart illustrates how Aura Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Aura Biosciences Inc stock price today for real-time trading data and today's change.
Aura Biosciences Inc Cash Flow Conversion Ratio Explained
Aura Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aura Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aura Biosciences Inc ranked by their cash flow conversion efficiency. Also see Aura Biosciences Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guizhou Sanli Pharmaceutical Co Ltd
SHG:603439
|
0.021x |
|
Jiangsu Olive Sensors High-Tech Co Ltd
SHE:300507
|
-0.025x |
|
Ardmore Shipping Corporation
F:A61
|
0.075x |
|
Fujian Zhangzhou Development Co Ltd
SHE:000753
|
0.034x |
|
Tiptree Inc
NASDAQ:TIPT
|
0.000x |
|
Innova Captab Limited
NSE:INNOVACAP
|
0.027x |
|
SLR Investment Corp
NASDAQ:SLRC
|
0.017x |
|
Mega First Corporation Bhd
KLSE:3069
|
0.050x |
Annual Cash Flow Conversion Efficiency for Aura Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Aura Biosciences Inc from 2019 to 2025. Review AURA free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $136.91 Million | $-84.74 Million | -0.619x | -17.86% |
| 2024-12-31 | $151.97 Million | $-79.81 Million | -0.525x | -85.76% |
| 2023-12-31 | $225.85 Million | $-63.85 Million | -0.283x | -1.26% |
| 2022-12-31 | $195.58 Million | $-54.60 Million | -0.279x | -31.20% |
| 2021-12-31 | $152.31 Million | $-32.41 Million | -0.213x | +83.06% |
| 2020-12-31 | $19.36 Million | $-24.32 Million | -1.256x | -86.97% |
| 2019-12-31 | $30.76 Million | $-20.67 Million | -0.672x | -- |
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the … Read more